ASCO has hand selected PharmaMar’s (MSE:PHM) abstract 8906 for the “Best of ASCO” meetings in the summer over three US cities and 30 others over 5 continents.
Madrid, 15 de mayo de 2019.- ASCO has hand selected PharmaMar’s (MSE:PHM) abstract 8906 for the “Best of ASCO” meetings in the summer over three US cities and 30 others over 5 continents. The list of meetings can be seen at https://meetings.asco.org/boa/
Best of ASCO® is an educational initiative that condenses highlights from ASCO’s Annual Meeting into a two-day program. The purpose of this initiative is to increase global access to cutting-edge science. Abstracts were selected according to specific criteria and reflect research that is relevant and significant in oncology today. In addition to three domestic Best of ASCO® Meetings (Seattle, Austin, Baltimore), there will also be nearly thirty International and Officially Licensed Best of ASCO® Meetings.
“It is an honor to be selected in this small group of presentations labeled “Best of ASCO”. We are hoping to be able to offer a new therapeutic option for patients and physicians, the first since over twenty years, in second line lung cancer” said Luis Mora, General Manager of the Oncology Unit at PharmaMar.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical enterprise, Zelnova Zeltia. To learn more about PharmaMar, please visit us at www.pharmamar.com.
About lurbinectedin
Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.
Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Digital Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000
Investor Relations:
Phone: +34 914444500
Or please visit our website at www.pharmamar.com
